Has Helen Eshed, MD received payments from drug or device companies?

Yes. Drug and device makers reported $34,797 in general payments to Helen Eshed, MD across 80 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Helen Eshed, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Helen Eshed, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Helen Eshed, MD

Gynecologic Oncology · Austin, TXNPI 1215195516

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $26,116 of the $34,797 with a category attached, or 75.1%. AbbVie accounts for 96.2% of it on its own, with 20 other manufacturers making up the rest. 2025 is the largest year on record at $23,501, more than ten times the $18 reported in 2019.

$34,797in general payments, 2019–2025

Across 80 payments — averaging $434.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AbbVie$33K
Immunogen, Inc.$275
Myriad Genetic Laboratories, Inc.$162
AstraZeneca$151
Merck$151
GSK$95
plus $505 from 15 others

$3,486,739in research payments, 2019–2025

Across 43 payments — averaging $81,087 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Merck$3.1M
Regeneron$330K
AstraZeneca$15K
Genmab U.S., Inc.$12K
Incyte Corporation$134

What the payments were for

Consulting fees$3,37510%
Speaking & faculty fees$26,11675%
Travel & lodging$3,0959%
Food & beverage$2,2126%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AbbVie	32	$33,458
Immunogen, Inc.	2	$275
Myriad Genetic Laboratories, Inc.	6	$162
AstraZeneca	6	$151
Merck	6	$151
GSK	4	$95
Incyte Corporation	4	$86
Johnson & Johnson	4	$82
Eisai Inc.	2	$50
Novartis	2	$43
Astellas Pharma US Inc	2	$39
Edwards Lifesciences	1	$39
Tempus AI, Inc	1	$26
Daiichi Sankyo Inc.	1	$24
Takeda Pharmaceuticals U.S.A., Inc.	1	$22
AVEO Pharmaceuticals, Inc.	1	$20
Regeneron Healthcare Solutions, Inc.	1	$19
Ipsen Biopharmaceuticals, Inc	1	$19
Agios Pharmaceuticals, Inc.	1	$16
Jazz Pharmaceuticals Inc.	1	$14
Clovis Oncology, Inc.	1	$6

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Elahere$29,949

How this compares

$34,797 in reported general payments places this provider in the 80th percentile of 135 gynecologic oncology providers in Texas.

See all gynecologic oncology providers in Texas →

Medicare billing

Part B allowed, 2024

$158,916

Medicare patients

150

Services billed

5,292

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
EliquisApixaban	12	$6,934
Enoxaparin Sodium	12	$1,664
Estradiol	19	$1,242
Prednisolone Acetate	13	$493
Gabapentin	62	$353
Dexamethasone	36	$344
Prochlorperazine Maleate	28	$342
Letrozole	22	$326
Lidocaine-PrilocaineLidocaine/Prilocaine	26	$304
Oxycodone Hcl	31	$241
Neomycin Sulfate	30	$158
Ondansetron Hcl	25	$137
Ondansetron OdtOndansetron	11	$133
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst	11	$125
Olanzapine	25	$104

Paid to pharmacies, not to this prescriber.

Other gynecologic oncology in Austin

Priyanka KamathAustin$4K
Lynne KnowlesAustin$4K
Robert ColemanHouston$864K
Reagan StreetFort Worth$280K
Joseph de la GarzaSan Antonio$234K
Maurie MarkmanHouston$204K
Dustin MandersDallas$171K
Tiffany RedfernFort Worth$165K
Antonio Santillan-GomezSan Antonio$162K
Michael FrumovitzHouston$156K

See the full list for Texas →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →